CorMedix (CRMD)
(Delayed Data from NSDQ)
$11.64 USD
-0.03 (-0.26%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $11.64 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRMD 11.64 -0.03(-0.26%)
Will CRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRMD
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
Other News for CRMD
March 2026 Options Now Available For CorMedix (CRMD)
This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
CRMD Downgraded to Hold by D. Boral Capital | CRMD Stock News
Circle initiated, Disney upgraded: Wall Street's top analyst calls
CorMedix just downgraded at D. Boral Capital, here's why